605199.SH
Hainan Huluwa Pharmaceutical Group Co., Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 5.77
−1.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 710.1M | 900.8M | 1.4B | 1.8B | 1.5B |
| Cost of Revenue | 541.1M | 636.5M | 737.1M | 884.9M | 638.6M |
| Gross Profit | 169.0M | 264.4M | 676.4M | 910.3M | 876.5M |
| Operating Expenses | |||||
| R&D Expense | 89.9M | 93.9M | 202.1M | 113.7M | 105.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 117.0M | 123.6M | 119.5M | 96.3M | 69.8M |
| Selling & Marketing Expense | 197.5M | 231.6M | 610.6M | 638.2M | 584.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 458.1M | 504.9M | 981.1M | 882.2M | 790.4M |
| Cost and Expenses | 999.2M | 1.1B | 1.7B | 1.8B | 1.4B |
| Operating Income (EBIT) | (312.2M) | (260.4M) | (267.4M) | 28.5M | 96.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (320.5M) | (268.7M) | (269.2M) | 27.0M | 97.2M |
| Income Tax Expense | 16.7M | 15.7M | 351.3K | 10.1M | 12.5M |
| Bottom Line | |||||
| Net Income | (340.7M) | (287.4M) | (274.5M) | 10.9M | 85.7M |
| Earnings from Cont. Ops | (337.2M) | (284.3M) | (269.5M) | 21.7M | 84.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (340.7M) | (287.4M) | (274.5M) | 10.9M | 85.7M |
| Per Share | |||||
| Basic EPS | (CN¥0.89) | (CN¥0.72) | (CN¥0.69) | CN¥0.03 | CN¥0.21 |
| Diluted EPS | (CN¥0.89) | (CN¥0.72) | (CN¥0.69) | CN¥0.03 | CN¥0.21 |
| Revenue Per Share | CN¥1.72 | CN¥2.26 | CN¥3.55 | CN¥4.96 | CN¥3.79 |
| Shares | |||||
| Basic Shares Outstanding | 413.7M | 399.1M | 397.8M | 361.7M | 400.2M |
| Diluted Shares Outstanding | 413.7M | 399.1M | 397.8M | 361.7M | 400.2M |
| Profitability Metrics | |||||
| EBITDA | — | (161.7M) | (191.9M) | 81.7M | 143.4M |
| D&A | — | 98.7M | 75.5M | 53.2M | 46.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026